Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed cancer therapy, improving survival rates.
• However, many patients do not respond to ICIs or develop resistance, and severe immune-related adverse events (irAEs) limit their use.
• Challenges include poor drug accumulation at tumor sites and significant off-target toxicities.

Purpose of the Study:

• To review nanoparticles designed for direct targeting of the PD-1/PD-L1 axis in cancer treatment.
• To explore nanomedicine strategies combining anti-PD-1/PD-L1 agents with other therapies.
• To discuss the anticancer effects, safety profiles, and future potential of these nanomedicine-based treatments.

Main Methods:

• Summarizing research on nanoparticles engineered to target PD-1/PD-L1 interactions.
• Analyzing nanocarrier properties such as reduced off-target effects, biocompatibility, multifunctionality, and biomimetic modifications.
• Reviewing studies on combination therapies utilizing nanomedicine for enhanced cancer treatment.

Main Results:

• Nanoparticles improve the delivery efficacy of PD-1/PD-L1 inhibitors to tumor sites.
• Nanocarriers enhance anti-tumor immune responses and minimize severe side effects associated with ICIs.
• Targeted nanomedicine approaches show promise in overcoming resistance and improving safety.

Conclusions:

• Nanoparticle-based delivery systems offer a promising strategy to enhance the therapeutic index of PD-1/PD-L1 inhibitors.
• These nanocarriers can overcome limitations of conventional ICIs, improving efficacy and patient safety.
• Future research should focus on optimizing nanomedicine designs and combination strategies for broader clinical application.